Please login to the form below

Not currently logged in
Email:
Password:

Ariad founder Harvey Berger to retire as CEO and chairman

Effective from December 31 or upon finding of successor

edit-Harvey-BergerAriad Pharmaceuticals founder Harvey J. Berger has announced he will retire as CEO and chairman of the firm.

Berger founded Ariad 23 years ago and has served as its chairman and CEO since 1991, leading the company's growth into an integrated global oncology firm.

Commenting on his time with Ariad, Berger said: “I am proud to have worked with so many incredibly talented employees and together to have achieved so much for cancer patients in need of new treatment options where none exist.

“Ariad has been at the forefront of precision medicine initiatives in cancer, and I expect that the Company will continue to lead the way as new targeted therapies emerge from our drug-discovery platform – built on our computational and structural technologies.”

Under his leadership, Ariad brought Iclusig to the market for the treatment of patients with refractory chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, approved in the US, EU, Switzerland, Australia, Canada and Israel. 

Marty Duvall, executive VP and chief commercial officer at Ariad, added: “Harvey enthusiastically embraced the evolution of ARIAD into a global commercial company. His pride, satisfaction and commitment to deliver on the vision of transforming patient-lives motivates the commercial team each and every day.”

5th May 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...